Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
Completed
Tetraphase Pharmaceuticals, Inc.
Phase 2
2011-01-01
This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to
assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared
with ertapenem in the treatment of adult community-acquired complicated intra-abdominal
infections (cIAIs).
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
Completed
Tetraphase Pharmaceuticals, Inc.
Phase 3
2013-08-01
This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to
assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in
the treatment of adult complicated intra-abdominal infections (cIAI).
A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization
Completed
Tetraphase Pharmaceuticals, Inc.
Phase 1
2013-03-01
This is a randomized, placebo- and positive-controlled (moxifloxacin), 3-period, 3-way
crossover thorough QT study, which includes a Screening Period, Treatment Periods (1 through
3), and a Follow-up Visit. Subjects will be confined to the investigational site for 4
nights/3 days during Period 1 and for 3 nights/2 days during Periods 2 and 3. There will be a
minimum of a 14 day washout between treatments.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
